Table 6.
Fully adjusted* relative risks (RR) and 95% confidence intervals (CI) comparing risk for postpartum hemorrhage among pregnant women with current exposure by dose†
| Total | No (%) of women with postpartum hemorrhage | RR (95% CI) | |
|---|---|---|---|
| SRI monotherapy: | |||
| High | 1597 | 66 (4.1) | 1.55 (1.21 to 1.97) |
| Medium | 7877 | 324 (4.1) | 1.51 (1.34 to 1.70) |
| Low | 3236 | 113 (3.5) | 1.29 (1.07 to 1.55) |
| Non-SRI monotherapy: | |||
| Medium or high | 419 | 12 (2.9) | 1.07 (0.61 to 1.88) |
| Low | 1074 | 44 (4.1) | 1.49 (1.11 to 2.00) |
| Unexposed | 69 044 | 1896 (2.8) | Reference |
SRI=serotonin reuptake inhibitor.
*Delivery year, age, race, multiple pregnancy, diabetes, coagulopathy, number of outpatient mood/anxiety disorder diagnoses, number of inpatient mood/anxiety disorder diagnoses, psychotic disorder, other mental health disorder, pain indication, sleep disorder, anticonvulsant dispensing, benzodiazepine dispensing, aspirin dispensing, heparin dispensing, low molecular weight heparin dispensing, and number of outpatient visits and days in hospital during baseline.
†Dose levels were defined according to Goodman & Gilman’s usual dose (mg/day):26 low <lowest usual dose, medium ≤midpoint of usual dose range, high >midpoint of usual dose range.